title: Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice.
abstract: In a multicenter randomized double-blind study we demonstrated that Qiliqiangxin (QLQX), a traditional Chinese medicine, had a protective effect in heart failure patients. However, whether and via which mechanism QLQX attenuates cardiac remodeling after acute myocardial infarction (AMI) is still unclear. AMI was created by ligating the left anterior descending coronary artery in mice. Treating the mice in the initial 3 days after AMI with QLQX did not change infarct size. However, QLQX treatment ameliorated adverse cardiac remodeling 3 weeks after AMI including better preservation of cardiac function, decreased apoptosis and reduced fibrosis. Peroxisome proliferator-activated receptor-γ (PPARγ) was down-regulated in control animals after AMI and up-regulated by QLQX administration. Interestingly, expression of AKT, SAPK/JNK, and ERK was not altered by QLQX treatment. Inhibition of PPARγ reduced the beneficial effects of QLQX in AMI remodeling, whereas activation of PPARγ failed to provide additional improvement in the presence of QLQX, suggesting a key role for PPARγ in the effects of QLQX during cardiac remodeling after AMI. This study indicates that QLQX attenuates cardiac remodeling after AMI by increasing PPARγ levels. Taken together, QLQX warrants further investigation as as a therapeutic intervention to mitigate remodeling and heart failure after AMI.
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Lichan
authors: L
authors: Tao
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Sutong
authors: S
authors: Shen
authors: Regeneration and Ageing Lab and Experimental Center of Life Sciences, School of Life Science, Shanghai University, Shanghai 200444, China.
authors: Siyi
authors: S
authors: Fu
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Hongyi
authors: H
authors: Fang
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Xiuzhi
authors: X
authors: Wang
authors: Cardiovascular Division of the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
authors: Saumya
authors: S
authors: Das
authors: Laboratory of Experimental Cardiology, University Medical Centre Utrecht, Utrecht 3508, The Netherlands.
authors: Joost P G
authors: JP
authors: Sluijter
authors: Cardiovascular Division of the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
authors: Anthony
authors: A
authors: Rosenzweig
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Yonglan
authors: Y
authors: Zhou
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Xiangqing
authors: X
authors: Kong
authors: 1] Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China [2] Regeneration and Ageing Lab and Experimental Center of Life Sciences, School of Life Science, Shanghai University, Shanghai 200444, China.
authors: Junjie
authors: J
authors: Xiao
authors: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors: Xinli
authors: X
authors: Li
mesh_terms: D000818:Animals; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009124:Muscle Proteins / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D047495:PPAR gamma / Q000378:metabolism; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D004365:Drugs, Chinese Herbal; D009124:Muscle Proteins; D047495:PPAR gamma; C572413:qiliqiangxin